Matteo Dal PeraroMatteo Dal Peraro graduated in Physics at the University of Padua in 2000. He obtained his Ph.D. in Biophysics at the International School for Advanced Studies (SISSA, Trieste) in 2004. He then received postdoctoral training at the University of Pennsylvania (Philadelphia) under the guidance of Prof. M. L. Klein. He was nominated Tenure Track Assistant Professor at the EPFL School of Life Sciences in late 2007.
His research at the Laboratory for Biomolecular Modeling (LBM), within the Interfaculty Institute of Bioengineering (IBI), focuses on the multiscale modeling of large macromolecular systems.
Theo LasserDe nationalité allemande, né en 1952 à Lauchheim (Baden-Württemberg). Après des études de physique à l'Université Fridericiana de Karlsruhe, il y obtient son diplôme de physique en 1978.
En 1979, il rejoint l'Institut de Recherches franco-allemand à Saint-Louis (France) comme collaborateur scientifique. En 1986, il rejoint la division de recherche de Carl Zeiss à Oberkochen (Allemagne) où il développe principalement divers systèmes laser pour des applications médicales. Dès 1990, il dirige le laboratoire laser de la division médicale. En 1993, il prend la direction de l'unité "laser d'ophtalmologie". Dès le début 1995, il est chargé de restructurer et regrouper les nombreuses activités d'ophtalmologie chez Carl Zeiss et de les transférer à Jena. Durant cette période, il réalise des nouveaux instruments de réfraction, des biomicroscopes et des caméras rétiniennes.
Dès janvier 1998, il dirige la recherche de Carl Zeiss à Jena où il initie de nouveaux projets en microscopie, en microtechnique et en recherche médicale. En juillet 1998, il est nommé professeur ordinaire en optique biomédicale à l'Institut d'optique appliquée. Au sein du Département de microtechnique, son activité de recherche porte sur la photonique biomédicale. Il participe à l'enseignement d'optique et d'instrumentation biomédicale.
Short CV
1972 Physics University of Karlsruhe (Germany)
1979 l'Institut de Recherches franco-allemand à Saint-Louis (France)
1986 central research division Carl Zeiss, Oberkochen (Germany)
1990 Med - Division, ophthalmic lasers
1994 Ophthalmology division, Carl Zeiss Jena
1998 Head of Central research Carl Zeiss Jena
1998 full Professor Ecole Polytechnique Federale Lausanne, Switzerland
Gerardo TurcattiSenior scientific level (R&D) with extensive experience in the management of multidisciplinary technological projects. Prof. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL he created in 2006. In the framework of the NCCR-Chemical Biology, he is project leader of the program ACCESS (An Academic Chemical Screening Platform for Switzerland). Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed high throughput DNA sequencing technologies currently owned by Illumina and used in the ‘Next Generation Sequencing’ instruments. Prior to this experience, Prof. Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Chemical Biology, Bio-analytical Chemistry, DNA and Protein Chemistry. Prof. Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Michel AguetDr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Aleksandra RadenovicFrom April 2021 Full Professor 2015 -2021 Associate Professor2008-2015 Tenure-Track Assistant Professor2004-2007 Postdoc at the University of California, Berkeley in the group of Prof.Liphardt2003 PhD student of Prof. Dietler in Laboratory of Physics of Living Matter, University of Lausanne 1999 Diploma thesis on the subject of the Raman spectroscopy of beta carotene1994-1999 Physics department at the University of Zagreb1994 baccalaureate, Classical gymnasium
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
